UPLIFT reassures some over Spiriva CV safety
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim/Pfizer's leading COPD treatment Spiriva (tiotropium bromide) failed to reduce the rate of decline in FEV
You may also be interested in...
Novavax’s COVID-19 Vaccine Boost From First Phase I Data
A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.
Acadia Hit By Two Surprise Disappointments With Nuplazid
A couple of unexpected events for pimavanserin mean that Acadia will drop its development for major depressive disorder and have to wait a little longer to hear if it can launch the product for dementia-related psychosis, a large potential indication.
US Approval For ViiV’s ‘Last Resort’ HIV Drug Rukobia
The US FDA has given the go-ahead for marketing of ViiV healthcare’s novel HIV drug just as the EMA removes the accelerated assessment status from its application there.
Need a specific report? 1000+ reports available
Buy Reports